Seer CEO Omid Farokhzad Makes Unsolicited $2.45/Share Offer to Buy the Company
The Board will form a Special Committee to evaluate the offer.
Already have an account? Sign in.
The Board will form a Special Committee to evaluate the offer.
Roth Capital maintains a Buy rating with a $9 price target despite the post-deal share decline.
BMO Capital gives Trevi Therapeutics an Outperform rating and $36 target, citing strong potential for Haduvio as a first-in-class treatment for chronic cough in idiopathic pulmonary fibrosis.
Analyst forecasts show Intel and Samsung struggling to close the gap on A16 and N2 technology.